Myasthenia gravis

BMJ (Online)

Volumn 345, Issue 7891, 2013, Pages

  Spillane, J ^a   Higham, E ^b   Kullmann, D M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Central Medical Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CORTICOSTEROID; CREATINE KINASE; CYCLOSPORIN A; EDROPHONIUM CHLORIDE; IMMUNOGLOBULIN; MAGNESIUM; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITUXIMAB; TACROLIMUS;

CEREBROVASCULAR ACCIDENT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DYSPHAGIA; ELECTROMYOGRAPHY; ENDROPHONIUM TEST; FATIGUE; HISTORY; HUMAN; ICE TEST; LABORATORY TEST; MOTOR NEURON DISEASE; MYASTHENIA GRAVIS; NERVE STIMULATION; NEUROMUSCULAR DISEASE; NOTE; PARKINSON DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; SLURRED SPEECH; THYMECTOMY; UNSPECIFIED SIDE EFFECT; WEAKNESS;

EID: 84872743013     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e8497     Document Type: Note

References (19)

1. Skeie GO, Romi F. Paraneoplastic myasthenia gravis: immunological and clinical aspects. Eur J Neurol 2008;15:1029-33.
2. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-9.
3. Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci 2007;15;261:127-33.
4. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010;10:46.
5. Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatr 1998;65:492-6.
6. Phillips LH, 2nd. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003;998:407-12.
7. Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 2008;1132:238-43.
8. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997;244:112-8.
9. Libman R, Benson R, Einberg K. Myasthenia mimicking vertebrobasilar stroke. J Neurol 2002;249:1512-4.
10. Montero-Odasso M. Dysphonia as first symptom of late-onset myasthenia gravis. J Gen Intern Med 2006;21:C4-6.
11. Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatr 2003;74:1105-8.
12. Palace J, Vincent A, Beeson D. Myasthenia gravis: diagnostic and management dilemmas. Curr Opin Neurol 2001;14:583-9.
13. Reddy AR, Backhouse OC. "Ice-on-eyes", a simple test for myasthenia gravis presenting with ocular symptoms. Pract Neurol 2007;7:109-11.
14. Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007;36:651-8.
15. AAEM Quality Assurance Committee, American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001;24:1239-47.
16. Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil 2005;84:627-38.
17. Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis 2011. doi:10.4061/2011/847393.
18. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893-902.
19. Collongues N, Casez O, Lacour A, Tranchant C, Vermersch P, de Seze J, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve 2012;46:687-91.